Abstract:Carrilizumab, a PD-1 inhibitor, has shown therapeutic effectiveness in patients with late-stage or metastatic solid tumors exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). dMMR/MSI-H cancer patients are known to be responsive to PD-1 inhibitors. However, the use of carrilizumab for preoperative immunotherapy in early, unresectable MSI-H/dMMR primary colon cancer lesions is relatively underexplored. We present the case of a 46-year-old male who sought medical attention at our institution due to a history of hematochezia for two weeks, right-sided abdominal pain for one week, and loose stools. Imaging indicated duodenal involvement, and a biopsy confirmed ascending colon adenocarcinoma with MSI-H status. Given that the patient's family exhibited a history of more than three confirmed cases of colorectal cancer spanning two generations, Lynch syndrome was considered. After four cycles of PD-1 antagonist immunotherapy with carrilizumab, the patient's symptoms resolved, and physical examination revealed no abdominal tenderness or palpable masses. Following radical colectomy, the primary tumor exhibited a pathological complete response. This case highlights the potential of preoperative neoadjuvant immunotherapy to improve staging accuracy and increase surgical resection rates in T4b MSI-H colon cancer patients without distant metastasis, suggesting a need for reconsideration of the treatment approach. Carrilizumab, ein PD-1-Inhibitor, hat sich bei Patienten mit soliden Tumoren im Spätstadium oder mit Metastasen, die einen Mangel an DNA-Mismatch-Reparatur (dMMR) oder eine hohe Mikrosatelliteninstabilität (MSI-H) aufweisen, als therapeutisch wirksam erwiesen. dMMR/MSI-H-Krebspatienten sprechen bekanntermaßen gut auf PD-1-Inhibitoren an. Der Einsatz von Carrilizumab zur präoperativen Immuntherapie bei frühen, inoperablen MSI-H/dMMR-Kolonkarzinom-Primärläsionen ist jedoch noch relativ wenig erforscht. Wir stellen den Fall eines 46-jährigen Mannes vor, der sich wegen einer zweiwöchigen Hämatochezie, einwöchigen rechtsseitigen Bauchschmerzen und eines lockeren Stuhlgangs in unserer Einrichtung vorstellte. Die Bildgebung wies auf eine Beteiligung des Zwölffingerdarms hin, und eine Biopsie bestätigte ein Adenokarzinom des aufsteigenden Dickdarms mit MSI-H-Status. Da in der Familie des Patienten über zwei Generationen hinweg mehr als drei bestätigte Fälle von Darmkrebs aufgetreten waren, wurde das Lynch-Syndrom in Betracht gezogen. Nach vier Zyklen einer PD-1-Antagonisten-Immuntherapie mit Carrilizumab klangen die Symptome des Patienten ab, und bei der körperlichen Untersuchung wurden keine abdominalen Schmerzen oder tastbare Massen festgestellt. Nach der radikalen Kolektomie zeigte der Primärtumor ein pathologisch vollständiges Ansprechen. Dieser Fall unterstreicht das Potenzial der präoperativen neoadjuvanten Immuntherapie zur Verbesserung der Staging-Genauigkeit und zur Erhöhung der chirurgischen Resektionsraten bei T4b MSI-H-Darmkrebspatienten ohne Fernmetastasen, was auf die Notwendigkeit eines Überdenkens des Behandlungsansatzes hinweist. Received: 05 December 2023 Article published online: 11 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies

Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer

Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Microsatellite Instability-High Gastrointestinal Malignancies: A Case Series

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy

Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report

Organ Preservation in Locally Advanced Colorectal Cancer with Microsatellite Instability-High after Immunotherapy

Efficacy and Safety of Preoperative Immunotherapy in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Gastrointestinal Malignancies

Neoadjuvant immunotherapy with ipilimumab plus nivolumab in mismatch repair deficients/microsatellite instability-high colorectal cancer: a preliminary report of case series

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Use of Chemoimmunotherapy for Locally Advanced Deficient Mismatch Repair (dMMR) Gastric Adenocarcinoma With Curative Intent: A Case Report

Pathological Complete Response to Liver Metastasis With Pembrolizumab in a Previously Treated Patient With Microsatellite Instability-high Colorectal Cancer

Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H / dMMR rectal cancer: A prospective, multicenter, phase Ib study

Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions

PD-1 blockade boosted chemo-target therapy in cT4NxM0 pMMR/MSS colorectal cancer.

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors